Ascento-CDA

Ascento-CDA is developing a digital health platform that provides personalized disease management strategies in the field of cognitive decline, dementia and Alzheimer’s disease (CDA). Powered by AI and Machine Learning, it is the first solution that yields evidence-based directions for therapeutic interventions in this field. It is known that by diagnosing and treating underlying conditions, it is possible to stop, delay or even revert decline. By use of Machine Learning and AI, Ascento-CDA discovers and provides analysis of the Immunologic and Inflammatory pathways connected between background diseases which are specific to cognitive decline in the patient. This yields a Root-Cause-Analysis, from which guidelines are generated for clinicians to follow and address underlying diseases and conditions. There are more than 600 research programs that have proven these correlations, but till date, few medical professionals have developed working solutions to provide personalized guidelines for CDA remediation. There are more than 55 million Cognitive Decline/Dementia patients in the world with 78 million forecasted by the year 2030. In the US the burgeoning annual cost of managing a CDA patient is around $50.000. The few drug solutions available are very expensive and offer limited relief.